Daily Newsletter

28 June 2023

Daily Newsletter

28 June 2023

Astellas reports data from Phase IIIb trial to treat VMS due to menopause

At week 24, the study met the primary objective, demonstrating a significant reduction from baseline in the frequency of VMS.

June 28 2023

Astellas Pharma has reported positive topline results from the Phase IIIb DAYLIGHT clinical trial of fezolinetant for the treatment of vasomotor symptoms (VMS) due to menopause.

The placebo-controlled, randomised, double-blind study is designed to evaluate the safety and efficacy of the investigational, oral, non-hormonal compound fezolinetant in menopausal women with moderate to severe VMS.

It enrolled 453 women aged 40-65 years from 69 sites in Turkey, Europe, and Canada.

Menopausal women who are considered unsuitable for hormone therapy received 45mg fezolinetant once daily for 24 weeks or a placebo.

At week 24, the study met the primary objective, demonstrating a statistically significant reduction from baseline in the frequency of moderate to severe VMS.

Less than 5% of patients showed common adverse treatment-emergent events of headaches and Covid-19.

Additional safety and efficacy data from the DAYLIGHT study will be used to support reimbursement dossiers throughout Europe and health technology assessments.

Fezolinetant, a neurokinin 3 (NK3) receptor antagonist, is available as VEOZAH in the US.

Astellas biopharma development head and vice-president Marci English said: “These 24-week placebo-controlled data add to our growing base of clinical evidence established in the SKYLIGHT studies and provide additional insights on the safety and effectiveness of fezolinetant in women who cannot, or choose not to, take hormone therapy.”

Last year, Astellas Pharma reported topline findings from the Phase III MOONLIGHT 3 clinical trial of fezolinetant to treat moderate to severe VMS linked to menopause in women in mainland China.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close